1. Szerszen A, Gupta S, Seminara D, Jarrett M, Goldstein M. Peritoneal tuberculosis complicated by immune recon- stitution inflammatory syndrome in a patient treated with infliximab?: a case for adjuvant immunosuppressive therapy. J Clin Rheumatol. 2009; 15:417–8.
2. Verhave JC, van Altena R, Wijnands MJ, Roerdink HT. Tuberculous peritonitis during infliximab therapy. Neth J Med. 2008; 66:77–80.
3. Matsumoto T, Tanaka T, Kawase I. Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med. 2006; 355:740–1.
Article
4. Gutié rrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P, Miguel-de la Villa F. Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol. 2007; 26:452–3.
Article
5. Szeto T, Peterson J, Silva F. A case of tuberculous peritonitis in the United States in a patient with rheumatoid arthritis treated with adalimumab. J Clin Rheumatol. 2010; 16:135–7.
Article
6. Antolín J, Azahara M, Hernández C, Blanco M, Mao L, Cigüenza R. Tuberculous peritonitis after treatment with adalimumab. Scand J Infect Dis. 2008; 40:677–8.
Article
7. Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol. 2003; 21:526.
8. Park H, Park CW, Kim KB, Lee MJ, Zeon SJ, Shim SC, et al. A case of peritoneal tuberculosis with poncet's disease in a patient treated with infliximab. J Rheum Dis. 2011; 18:55–9.
Article
9. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009; 60:1884–94.
Article
10. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, Chan J, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis. 2007; 195:1643–50.
Article
11. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, et al. RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of an-ti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther. 2006; 8:R114.
12. Chow KM, Chow VC, Hung LC, Wong SM, Szeto CC. Tuberculous peritonitis-associated mortality is high among patients waiting for the results of mycobacterial cultures of ascitic fluid samples. Clin Infect Dis. 2002; 35:409–13.
Article
13. Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006; 367:1328–34.
Article
14. Yuksel H, Akoğlu TF. Serum and synovial fluid adenosine deaminase activity in patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis. 1988; 47:492–5.
Article
15. Riquelme A, Calvo M, Salech F, Valderrama S, Pattillo A, Arellano M, et al. Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis. J Clin Gastroenterol. 2006; 40:705–10.